These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31913230)

  • 1. Safety of vaginal estrogens: a systematic review.
    Crandall CJ; Diamant A; Santoro N
    Menopause; 2020 Mar; 27(3):339-360. PubMed ID: 31913230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study.
    Fernandes T; Pedro AO; Baccaro LF; Costa-Paiva LH
    Menopause; 2018 Jun; 25(6):641-647. PubMed ID: 29462095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial.
    Paraiso MFR; Ferrando CA; Sokol ER; Rardin CR; Matthews CA; Karram MM; Iglesia CB
    Menopause; 2020 Jan; 27(1):50-56. PubMed ID: 31574047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local oestrogen for vaginal atrophy in postmenopausal women.
    Suckling J; Lethaby A; Kennedy R
    Cochrane Database Syst Rev; 2006 Oct; (4):CD001500. PubMed ID: 17054136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local oestrogen for vaginal atrophy in postmenopausal women.
    Suckling J; Lethaby A; Kennedy R
    Cochrane Database Syst Rev; 2003; (4):CD001500. PubMed ID: 14583935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial.
    Fernandes T; Costa-Paiva LH; Pedro AO; Baccaro LF; Pinto-Neto AM
    Menopause; 2016 Jul; 23(7):792-8. PubMed ID: 27116462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic estradiol levels with low-dose vaginal estrogens.
    Santen RJ; Mirkin S; Bernick B; Constantine GD
    Menopause; 2020 Mar; 27(3):361-370. PubMed ID: 31794498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy.
    Crandall C
    J Womens Health (Larchmt); 2002 Dec; 11(10):857-77. PubMed ID: 12626086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy.
    Ulrich LS; Naessen T; Elia D; Goldstein JA; Eugster-Hausmann M;
    Climacteric; 2010 Jun; 13(3):228-37. PubMed ID: 20423243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Melisko ME; Goldman ME; Hwang J; De Luca A; Fang S; Esserman LJ; Chien AJ; Park JW; Rugo HS
    JAMA Oncol; 2017 Mar; 3(3):313-319. PubMed ID: 27832260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review.
    Simon JA; Archer DF; Constantine GD; Pickar JH; Amadio JM; Bernick B; Graham S; Mirkin S
    Maturitas; 2017 May; 99():51-58. PubMed ID: 28364869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective treatment of vaginal atrophy with isoflavone vaginal gel.
    Lima SM; Yamada SS; Reis BF; Postigo S; Galvão da Silva MA; Aoki T
    Maturitas; 2013 Mar; 74(3):252-8. PubMed ID: 23312487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women.
    Goldstein I; Alexander JL
    J Sex Med; 2005 Sep; 2 Suppl 3():154-65. PubMed ID: 16422792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial safety of ultra-low-dose estradiol vaginal tablets.
    Simon J; Nachtigall L; Ulrich LG; Eugster-Hausmann M; Gut R
    Obstet Gynecol; 2010 Oct; 116(4):876-883. PubMed ID: 20859151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does age at the start of treatment for vaginal atrophy predict response to vaginal estrogen therapy? Post hoc analysis of data from a randomized clinical trial involving 205 women treated with 10 μg estradiol vaginal tablets.
    Derzko CM; Röhrich S; Panay N
    Menopause; 2020 Oct; 28(2):113-118. PubMed ID: 33038141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy.
    Simon JA; Maamari RV
    Climacteric; 2013 Aug; 16 Suppl 1():37-43. PubMed ID: 23848490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.
    Hirschberg AL; Sánchez-Rovira P; Presa-Lorite J; Campos-Delgado M; Gil-Gil M; Lidbrink E; Suárez-Almarza J; Nieto-Magro C
    Menopause; 2020 May; 27(5):526-534. PubMed ID: 32049923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
    Al-Baghdadi O; Ewies AA
    Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses.
    Antoniou G; Kalogirou D; Karakitsos P; Antoniou D; Kalogirou O; Giannikos L
    Maturitas; 1997 Mar; 26(2):103-11. PubMed ID: 9089559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.